Helix BioPharmaHBPCF 28 EV-to-FCF is -32.04 as of Jun. 25, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 330 Biotechnology companies, Helix BioPharma ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Helix BioPharma's Enterprise Value is $74.30 Mil.
Helix BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was $-2.32 Mil. Therefore, Helix BioPharma's EV-to-FCF for today is -32.04.
The historical rank and industry rank for Helix BioPharma's EV-to-FCF or its related term are showing as below:
HBPCF'
s EV-to-FCF Range Over the Past 10 Years
Min: -30.9 Med: 0 Max: 0
Current: -30.9
HBPCF's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs HBPCF: -30.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Helix BioPharma's PE Ratio (TTM) for today is calculated as:
Helix BioPharma's share price for today is $1.71.
Helix BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Helix BioPharma EV-to-FCF Related Terms
Helix BioPharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helix BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's EV-to-FCF falls into.
Helix BioPharma's current Enterprise Value is $74.30 Mil.
Helix BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a EV-to-FCF of -32.04 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #999999 out of 330 companies in the Biotechnology industry.
Is Helix BioPharma's EV-to-FCF too high?
Helix BioPharma's current EV-to-FCF is -32.04. Based on the distribution chart, Helix BioPharma ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #999999 out of 330 companies for EV-to-FCF. This places Helix BioPharma in the lower half of its industry. The industry median EV-to-FCF is 14.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current EV-to-FCF is -32.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current EV-to-FCF of -32.04. The current EV-to-FCF is -32.04. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current EV-to-FCF is -32.04 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
